Ucla Clinical Trial Agreement

Responsibility for managing agreements related to sponsored research and other sponsored activities of the project is distributed among different UCLA administrative offices, based on the sponsor and the type of transaction. In some cases, several offices may share responsibility for different aspects of the negotiation and management of the transaction/agreement. PRINCETON, N.J.— (BUSINESS WIRE) -Advaxis, Inc (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a cooperation agreement with the University of California Los Angeles (UCLA) to conduct preclinical studies to evaluate the company`s Lm technology in multiform Glioblastom (GBM) mouse tumor models. In particular, collaboration with Dr. Vaithi Arumugaswami`s group in the Department of Molecular and Medical Pharmacology at UCLA will investigate anti-tumor immunity and anti-tumor reactions generated by Lm vaccines expressing different neo-anti-tumor glioblastoma. Various statements in this press release on Rocket`s future expectations, plans and prospects, including, but not only, Rocket`s security expectations, effectiveness and timing of product candidates, the Rocket can develop, also in collaboration with academic partners, to treat Fanconi anemia (FA), leukocyte deficiency I (LAD-I), pyruvate kinase (P Malignant infant osteoopetosis (IMO) and Danon disease (IMO) the efficacy and timing of related preclinical and clinical trials may make forward-looking statements within the meaning of the provisions of the Private Securities Litigation Reform Act 1995 and other federal securities laws and are subject to risks , uncertainties and important assumptions. You should not rely on these forward-looking statements that often contain words such as “believe,” “wait,” “anticipate,” “plan,” “give,” “appreciate,” “seek,” “may,” “suggest” or similar terms, variations of those terms or the negative of those terms. While Rocket believes that the expectations expressed in the forward-looking statements are reasonable, Rocket cannot guarantee such results. Actual results may differ materially from the results of these forward-looking statements, including, without limitation, Rocket`s ability to successfully demonstrate the efficacy and safety of these products, as well as preclinical and clinical trials; its gene therapy programs, preclinical and clinical results for its product candidates who may not support a new development and marketing authorization, Rocket`s ability to initiate a CEW registration study within projected timeframes, the potential benefits of Rocket candidates, actions taken by regulators that may influence the launch, timing and advancement of preclinical trials and clinical studies of its candidates, rocket and licensees. , the timing, costs or other aspects of a potential commercial launch of Rocket`s product candidates, Rocket`s ability to manage operating costs, Rocket`s ability to obtain additional funds to support its business activities, establish and maintain strategic business alliances and new business initiatives, Rocket`s reliance on third parties for product development, production, marketing, distribution and distribution, litigation and unforeseen expense outcomes, and risks addressed in the “Risk Factors” section of Rocket`s Annual Report on Form 10-K for the year past December 31, 2018.

Comments are closed.